FDA grants orphan drug status to AstraZeneca cancer drug
3rd Nov 2005, 02:36 GMT
The FDA has granted orphan drug designation for AstraZeneca's Zactima, which is designed for the treatment of patients with different forms of thyroid cancer.
FDA grants orphan drug status to AstraZeneca cancer drug related news:
- AstraZeneca Files for New Toprol Version — FDA News News from StratCenter.com
- AstraZeneca Submits New Drug Application for TOPROL-XL /Hydrochlorothiazide Combination Tablets for the Mgmt of Hypertension — Pharmaceuticals News from StratCenter.com
- AstraZeneca Proposes Mandatory FDA Review of All Pharmaceutical Direct-To-Consumer Advertising — Executive Announcements News from StratCenter.com
- Drug company proposes FDA check all drug advertising prior to marketing — News-Medical News Feed
- Caprion and AstraZeneca enter prostate cancer partnership — Pharmaceutical Business Review Online
- FDA Approves 1st New Therapy in 9 Years for Treatment of Advanced Pancreatic Cancer — Government/ Industry Regulation News from StratCenter.com
- FDA decision boosts Biogen Idec — Partnerships/ Joint Ventures News from StratCenter.com
- FDA Announces the Use of New Electronic Drug Labels to Help Better Inform the Public and Improve Patient Safety — Food and Drug Administration
- FDA Approves New Cancer Drug — ConsumerAffairs.Com News for Seniors
- FDA Expedites Review of Erbitux for Head, Neck Cancers — KeralaNext: International
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol